aromasil has been researched along with Hormone-Dependent Neoplasms in 63 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (3.17) | 18.2507 |
| 2000's | 36 (57.14) | 29.6817 |
| 2010's | 25 (39.68) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| He, Y; Huang, Y; Wang, C; Wu, K; Zhang, J; Zheng, S | 1 |
| Bachelot, T; Racadot, S; Visy, A | 1 |
| Chia, SK; Wilson, S | 1 |
| Bourgeois, H; de Boer, RH; Ferrero, JM; Gansert, JL; Jacot, W; Kaufman, PA; Kennecke, H; Loh, E; McCaffery, I; McGreivy, J; Robertson, JF; Suzuki, S; Zhu, M | 1 |
| Chishima, T; Hozumi, Y; Ikeda, M; Ishikawa, T; Iwase, H; Iwata, H; Saji, S; Toyama, T; Yamamoto, Y; Yamamoto-Ibusuki, M; Yamashita, H | 1 |
| Beck, JT; Brechenmacher, T; Campone, M; Dakhil, S; Deleu, I; Douma, S; El-Hashimy, M; Geberth, M; Hart, L; Heng, DY; Hortobagyi, GN; Lebrun, F; Masuda, N; Melichar, B; Nunzi, M; Piccart, M; Pistilli, B; Ringeisen, F; Rugo, HS | 1 |
| Brufsky, A; Mathew, A | 1 |
| Badovinac-Crnjevic, T; Chalchal, H; Chapman, JA; Cheung, AM; Elliott, CR; Goss, PE; Hershman, DL; Ingle, JN; Khosla, S; Linden, HM; Muss, HB; Pritchard, KI; Rowland, K; Scher, J; Shepherd, LE; St Louis, J; Stearns, V | 1 |
| Nagykálnai, T | 1 |
| Bachelot, T; Crétin, J; Debled, M; Delozier, T; Falandry, C; Freyer, G; Mauriac, L; Mille, D; Pujade-Lauraine, E; Romestaing, P; You, B | 1 |
| Glück, S | 1 |
| Beex, LV; de Jong, RS; Maartense, E; Meershoek-Klein Kranenbarg, WM; Nortier, JW; Putter, H; Roumen, RM; Seynaeve, C; van de Velde, CJ; van Nes, JG | 1 |
| Chan, MS; Chanplakorn, N; Chanplakorn, P; Miki, Y; Ono, K; Saji, S; Sasano, H; Suzuki, T; Toi, M; Ueno, T | 1 |
| Cartei, G; Endri, M; Fassina, A; Serino, FS; Zustovich, F | 1 |
| Domchek, SM; Dorazio, P; Gartner, EM; Khaira, D; Khalil, M; LoRusso, PM; Mariani, GL; Rüter, J; Soulieres, D; Trosko, JA; Usari, T; Vonderheide, RH | 1 |
| Agrawal, K; Mortimer, JE; Onami, S; Pal, SK | 1 |
| Christiaens, MR; De Smet, L; Dieudonné, AS; Henry, NL; Leunen, K; Lintermans, A; Morales, L; Neven, P; Pans, S; Paridaens, R; Timmerman, D; Van Calster, B; Van Hoydonck, M; Vergote, I; Verhaeghe, J; Verschueren, K; Westhovens, R; Wildiers, H | 1 |
| Aihara, T; Hozumi, Y; Masuda, N; Ohashi, Y; Ohsumi, S; Saito, T; Suemasu, K; Takehara, M; Takei, H | 1 |
| Chen, S; Hong, Y; Rashid, R | 1 |
| Landherr, L; Mészáros, E; Nagykálnai, T | 1 |
| Alés-Martínez, JE; Alvarez, I; Andrés, R; Antolín, S; Antón, A; Barnadas, A; Cámara, C; Carrasco, E; Casas, I; García Saenz, JA; Lao, J; Llombart-Cussac, A; Martín, M; Ruiz, A | 1 |
| Hozumi, Y; Ohashi, Y; Ohsumi, S; Shimozuma, K; Suemasu, K; Takehara, M; Takei, H | 1 |
| Carro, G; Harper, A; Hui, W; Lawton, J; Menas, P; Merkel, D | 1 |
| Azzouz, F; Desta, Z; Flockhart, DA; Hayden, J; Hayes, DF; Henry, NL; Lemler, S; Li, L; Nguyen, AT; Stearns, V; Storniolo, AM; Tarpinian, K; Yakim, E | 1 |
| Bartlett, JM; Beck, RA; Bloom, KJ; Dirix, L; Hasenburg, A; Kieback, D; Lawton, TJ; Markopoulos, C; Piper, T; Putter, H; Rea, D; Ring, BZ; Ross, DT; Seitz, RS; Seynaeve, C; van de Velde, CJ | 1 |
| Bhargava, R; Brufsky, AM; Davidson, NE | 1 |
| Bastiaannet, E; de Craen, AJ; Hasenburg, A; Hille, ET; Jones, SE; Liefers, GJ; Markopoulos, C; Paridaens, R; Putter, H; Rea, D; Seynaeve, C; van de Velde, CJ; van de Water, W; Westendorp, RG | 1 |
| Rose, C | 1 |
| Gershanovich, M; Mouridsen, H | 1 |
| Brodie, AH; Jelovac, D; Long, B | 1 |
| Ingle, JN | 2 |
| Ellis, MJ | 1 |
| Kawakami, M; Saji, S; Toi, M | 1 |
| Alvarez, I; Andersen, J; Bajetta, E; Bertelli, G; Bliss, JM; Carpentieri, M; Coates, AS; Cocconi, G; Coleman, RE; Coombes, RC; Delozier, T; Dodwell, D; Fallowfield, LJ; Gibson, LJ; Hall, E; Jassem, J; Jones, SE; Lønning, PE; Massimini, G; Mickiewicz, E; Ortmann, O; Paridaens, R; Snowdon, CF; Stewart, A; Stuart, N; van de Velde, C | 1 |
| Piccart-Gebhart, MJ | 1 |
| Altundag, K; Buzdar, AU; Hortobagyi, G; Morandi, P; Rouzier, R; Theriault, RL | 1 |
| Brodie, AM; Goloubeva, OG; Handratta, V; Ingle, JN; Jelovac, D; Long, BJ; Macedo, L | 1 |
| de Cremoux, P; Diéras, V; Fourquet, A; Magdelénat, H; Pierga, JY; Poupon, MF; Sigal-Zafrani, B | 1 |
| Caraglia, M; Cigolari, S; Colucci, G; Del Prete, S; Fanelli, F; Febbraro, A; Ferrari, E; Formato, R; Gebbia, V; Giotta, G; Iaffaioli, RV; Ianniello, G; Incoronato, P; Manzione, L; Marano, O; Marzano, N; Nasti, G; Pappagallo, G; Pedicini, T; Pezzella, G; Pisano, A; Pisconti, S; Pizza, C; Quattrin, S; Tortoriello, A | 1 |
| Hutchinson, L | 1 |
| Clemons, MJ; Freedman, OC; Verma, S | 1 |
| Canorea, F; Del Castillo, A; Gil, JM; González, P; Rubio-Terrés, C | 1 |
| Brown, MM; Manquez, ME; Shields, CL; Shields, JA | 1 |
| Chien, AJ; Goss, PE | 1 |
| Bria, E; Carlini, P; Cognetti, F; Giannarelli, D; Terzoli, E | 1 |
| Perez, EA | 1 |
| Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N | 1 |
| Bundred, NJ; Iddon, J | 1 |
| Eisen, A; Messersmith, H; Pritchard, KI; Shelley, W; Trudeau, M | 1 |
| Abbattista, A; Bapsy, P; Carpentieri, M; Dirix, LY; Falcon, S; Gomez, H; Ignacio, J; Jones, S; Lobelle, JP; Nag, S; Paridaens, R; Raghunadharao, D | 1 |
| Atkins, JN; Costantino, JP; Eisen, A; Farrar, WB; Fehrenbacher, L; Ganz, PA; Geyer, CE; Hoehn, JL; Hutchins, LF; Ingle, JN; Jeong, JH; Kroener, JF; Land, SR; Mamounas, EP; Pajon, ER; Robidoux, A; Smith, RE; Vogel, VG; Wickerham, DL; Wolmark, N | 1 |
| Aapro, M | 1 |
| Jassem, J | 1 |
| Adrover, E; Barnadas, A; Calvo, L; de la Haba, J; Estevez, LG; Gil, M; Llombart, A; Sánchez-Rovira, P | 1 |
| Lønning, PE | 1 |
| Harvey, HA; Santen, RJ | 1 |
| Attolico, M; Crucitta, E; De Lena, M; Lorusso, V; Mazzei, A; Sambiasi, D | 1 |
| Hamilton, A; Volm, M | 1 |
| Dixon, JM; Miller, WR | 1 |
| Buzdar, AU | 1 |
| Goss, PE | 1 |
| Lombardi, P | 1 |
22 review(s) available for aromasil and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasms, Hormone-Dependent; Network Meta-Analysis; Nitriles; Receptor, ErbB-2; Tamoxifen; Triazoles | 2017 |
[Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Humans; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Celecoxib; Estrogens; Female; Humans; Letrozole; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Pyrazoles; Randomized Controlled Trials as Topic; Recurrence; Salvage Therapy; Sulfonamides; Tamoxifen; Triazoles | 2010 |
[Aromatase inhibitors and arthralgia].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Medication Adherence; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Risk Factors; Triazoles | 2011 |
A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol Acetate; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
The role of aromatase inhibitors in the treatment of metastatic breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Triazoles | 2003 |
[Controversies in endocrine therapy for breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estrogen Replacement Therapy; Female; Humans; Letrozole; Mastectomy, Segmental; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Tamoxifen; Triazoles | 2004 |
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Enzyme Inhibitors; Evidence-Based Medicine; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Tamoxifen; Triazoles | 2004 |
[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Letrozole; Menopause; Neoplasms, Hormone-Dependent; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2004 |
Pre-menopausal breast cancer and aromatase inhibitors: Treating a new generation of women.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Therapy; Estrogens; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Premenopause; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles | 2006 |
Aromatase inhibitors and bone health in women with breast cancer.
Topics: Absorptiometry, Photon; Algorithms; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Remodeling; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Life Style; Neoplasms, Hormone-Dependent; Nitriles; Osteoporosis, Postmenopausal; Population Surveillance; Risk Factors; Triazoles | 2006 |
Safety of aromatase inhibitors in the adjuvant setting.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Causality; Chemotherapy, Adjuvant; Comorbidity; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Incidence; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Nitriles; Osteoporosis; Rats; Survival Analysis; Tamoxifen; Triazoles | 2007 |
To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision?
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Neoplasms, Hormone-Dependent; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2008 |
Neoadjuvant endocrine therapy for breast cancer: past, present and future.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Forecasting; Humans; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Patient Selection; Postmenopause; Tamoxifen; Triazoles | 2008 |
Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer.
Topics: Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Neoplasms, Hormone-Dependent; Postmenopause | 1998 |
Use of aromatase inhibitors in breast carcinoma.
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Design; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Premenopause; Tamoxifen; Triazoles | 1999 |
New aromatase inhibitors in the treatment of advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Double-Blind Method; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles | 2000 |
Nonsteroidal and steroidal aromatase inhibitors in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 2001 |
A summary of second-line randomized studies of aromatase inhibitors.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Drug Tolerance; Enzyme Inhibitors; Estrogen Receptor Modulators; Fadrozole; Female; Humans; Letrozole; Megestrol Acetate; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2001 |
Preliminary data from ongoing adjuvant aromatase inhibitor trials.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles | 2001 |
Exemestane, a new steroidal aromatase inhibitor of clinical relevance.
Topics: Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Receptor Modulators; Estrogens; Female; Humans; Neoplasms, Hormone-Dependent | 2002 |
19 trial(s) available for aromasil and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.
Topics: Aged; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Postmenopause; Receptor, ErbB-2 | 2013 |
Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prognosis; Receptors, Estrogen; Survival Rate; Toremifene | 2013 |
Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Receptors, Progesterone; Sirolimus | 2014 |
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bones of Lower Extremity; Breast Neoplasms; Calcium; Canada; Chemotherapy, Adjuvant; Dietary Supplements; Diphosphonates; Female; Fractures, Bone; Humans; Lumbar Vertebrae; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Radiography; Time Factors; Treatment Outcome; Triazoles; United States; Vitamin D | 2014 |
Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Celecoxib; Chemotherapy, Adjuvant; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasms, Hormone-Dependent; Placebos; Postmenopause; Prognosis; Pyrazoles; Soft Tissue Neoplasms; Sulfonamides; Survival Rate; Treatment Outcome | 2009 |
Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; International Agencies; Middle Aged; Neoplasms, Hormone-Dependent; Postmenopause; Practice Guidelines as Topic; Practice Patterns, Physicians'; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Tamoxifen; Treatment Outcome | 2010 |
Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells.
Topics: Aged; Aged, 80 and over; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; CTLA-4 Antigen; Drug Administration Schedule; Female; Humans; Inducible T-Cell Co-Stimulator Protein; Maximum Tolerated Dose; Middle Aged; Neoplasms, Hormone-Dependent; T-Lymphocytes | 2010 |
The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Japan; Lipids; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles; Triglycerides | 2011 |
Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Studies; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2012 |
Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Depression; Female; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Stress, Psychological; Surveys and Questionnaires; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Comorbidity; Female; Follow-Up Studies; Humans; Letrozole; Medication Adherence; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Prognosis; Prospective Studies; Triazoles; Withholding Treatment | 2012 |
Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study.
Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Immunohistochemistry; Neoplasms, Hormone-Dependent; Recurrence; Retrospective Studies; Risk Factors; Tamoxifen; Tissue Array Analysis | 2012 |
Elderly postmenopausal patients with breast cancer are at increased risk for distant recurrence: a tamoxifen exemestane adjuvant multinational study analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Postmenopause; Recurrence; Tamoxifen; Treatment Outcome | 2013 |
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
Topics: Administration, Oral; Aged; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Estrogen Antagonists; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Postmenopause; Receptors, Estrogen; Tamoxifen | 2004 |
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Enzyme Inhibitors; Evidence-Based Medicine; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Tamoxifen; Triazoles | 2004 |
Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 2005 |
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Estrogens; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Paclitaxel; Peripheral Nervous System Diseases; Tamoxifen | 2008 |
Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Celecoxib; Disease Progression; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Postmenopause; Pyrazoles; Sulfonamides; Tissue Distribution; Treatment Outcome | 2008 |
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
Topics: Administration, Oral; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Quality of Life; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome | 2008 |
23 other study(ies) available for aromasil and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Radiation recall syndrome in a patient with breast cancer, after introduction of everolimus.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Lobular; Estrogens; Everolimus; Female; Humans; Lymphatic Irradiation; Lymphocele; Mastectomy; Middle Aged; Neoplasms, Hormone-Dependent; Progesterone; Radiodermatitis; Radiotherapy, Intensity-Modulated; TOR Serine-Threonine Kinases | 2019 |
IGF-1R inhibition: right direction, wrong pathway?
Topics: Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent | 2013 |
The bone substudy of MA.27: does bone make a difference?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 2014 |
Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Estradiol Dehydrogenases; Estrogens; Female; Humans; Ki-67 Antigen; Mastectomy; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Postmenopause; Receptors, Steroid; Sulfatases | 2010 |
Differential diagnosis of lung nodules: breast cancer metastases and lung tuberculosis.
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Diagnosis, Differential; Estrogens; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoplasms, Hormone-Dependent; Progesterone; Recurrence; Tamoxifen; Tomography, X-Ray Computed; Tuberculosis, Pulmonary | 2010 |
Cognitive changes associated with endocrine therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Cognition; Cognition Disorders; Female; Humans; Letrozole; Memory; Neoplasms, Hormone-Dependent; Nitriles; Prospective Studies; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles; United States; Women's Health | 2010 |
Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Body Mass Index; Breast Neoplasms; Cohort Studies; Female; Hand Strength; Humans; Letrozole; Middle Aged; Musculoskeletal Diseases; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Syndrome; Tamoxifen; Triazoles | 2011 |
Binding features of steroidal and nonsteroidal inhibitors.
Topics: Amino Acids; Androgens; Androstadienes; Androstenedione; Aromatase; Aromatase Inhibitors; Binding Sites; Breast Neoplasms; Catalytic Domain; Estrogens; Estrone; Female; Humans; Letrozole; Mutagenesis, Site-Directed; NADPH-Ferrihemoprotein Reductase; Neoplasms, Hormone-Dependent; Nitriles; Protein Conformation; Structure-Activity Relationship; Triazoles | 2011 |
Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Female; Humans; Incidence; Neoplasms, Hormone-Dependent; Nitriles; Outpatients; Retrospective Studies; Triazoles | 2012 |
Prognostic/Predictive immunohistochemistry assays for estrogen receptor-positive breast cancer: back to the future?
Topics: Androstadienes; Breast Neoplasms; Female; Humans; Neoplasms, Hormone-Dependent; Tamoxifen; Tissue Array Analysis | 2012 |
The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens.
Topics: Androstadienes; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Cell Line, Tumor; Disease Models, Animal; Drug Administration Schedule; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
Sequencing of endocrine therapy in postmenopausal women with advanced breast cancer.
Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease Progression; Female; Humans; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Postmenopause; Receptors, Estrogen; Tamoxifen | 2004 |
Neoadjuvant endocrine therapy as a drug development strategy.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Celecoxib; Clinical Trials as Topic; Drug Design; Humans; Ki-67 Antigen; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Pyrazoles; Signal Transduction; Sulfonamides; Tamoxifen | 2004 |
New stars in the sky of treatment for early breast cancer.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Antagonists; Female; Humans; Neoplasms, Hormone-Dependent; Postmenopause; Tamoxifen | 2004 |
Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
Topics: Androstadienes; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Letrozole; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Random Allocation; Tamoxifen; Time Factors; Triazoles | 2004 |
Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Neoplasms, Hormone-Dependent; Postmenopause; Receptors, Estrogen; Tamoxifen | 2004 |
Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Computer Simulation; Cost-Benefit Analysis; Estrogen Antagonists; Estrogens; Fees, Pharmaceutical; Female; Follow-Up Studies; Humans; Letrozole; Markov Chains; Middle Aged; Models, Theoretical; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2006 |
Management of choroidal metastases from breast carcinomas using aromatase inhibitors.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Choroid Neoplasms; Combined Modality Therapy; Female; Humans; Letrozole; Mastectomy, Radical; Mastectomy, Segmental; Mastectomy, Simple; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Re: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Meta-Analysis as Topic; Neoplasms, Hormone-Dependent; Randomized Controlled Trials as Topic; Research Design; Survival Analysis | 2007 |
Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2008 |
Intergroup Exemestane Study mature analysis: overall survival data.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Neoplasms, Hormone-Dependent; Postmenopause; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Survival Rate; Tamoxifen | 2008 |
Local endocrine effects of aromatase inhibitors within the breast.
Topics: Anastrozole; Androstadienes; Aromatase; Aromatase Inhibitors; Breast; Breast Neoplasms; Cells, Cultured; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estrogens; Estrone; Female; Fibroblasts; Humans; In Vitro Techniques; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 2001 |
Estrogen as therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase II as Topic; Diethylstilbestrol; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estrogens; Female; Humans; Letrozole; Megestrol Acetate; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Salvage Therapy; Tamoxifen; Treatment Outcome; Triazoles | 2002 |